๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Locally Advanced or Metastatic Digestive Tract Tumors

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site๐Ÿ“ Taipei AP Biosciences Inc. ยท Tests: AP203, AP203 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Avapritinib Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357Phase 3272 sites๐Ÿ“ Scottsdale๐Ÿ“ Tucson๐Ÿ“ Tucson AstraZeneca ยท Tests: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors NCT05631964Phase 11 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites๐Ÿ“ Boston๐Ÿ“ Nashville๐Ÿ“ Adelaide Yuhan Corporation ยท Tests: YH32367 Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer NCT06893380n/a1 site๐Ÿ“ Seongnam-si CHA University ยท Tests: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab. A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-A1904 for Injection A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites๐Ÿ“ Santa Monica๐Ÿ“ New Have๐Ÿ“ Camperdown Kivu Bioscience Inc. ยท Tests: KIVU-107 Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273Phase 21 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 120 sites๐Ÿ“ Santa Monica๐Ÿ“ Atlanta๐Ÿ“ Jefferson Astellas Pharma Inc ยท Tests: ASP5834, panitumumab Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Nammi Therapeutics Inc ยท Tests: QXL138AM Injection every 2 weeks by IV Infusion EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EBNK-001 + IL-15 + Pembrolizumab A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites๐Ÿ“ Sacramento๐Ÿ“ Celebration๐Ÿ“ Miami Marengo Therapeutics, Inc. ยท Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites๐Ÿ“ Irvine๐Ÿ“ Los Angeles๐Ÿ“ Washington D.C. Exelixis ยท Tests: XB010, Pembrolizumab Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949Phase 21 site๐Ÿ“ Boston Beth Israel Deaconess Medical Center ยท Tests: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90 A Study of SH009 Injection in Patients With Advanced Solid Tumors. NCT07390838Phase 11 site๐Ÿ“ Shanghai Nanjing Sanhome Pharmaceutical, Co., Ltd. ยท Tests: SH009 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytrudaยฎ) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766Phase 1, Phase 242 sites๐Ÿ“ Duarte๐Ÿ“ Glendale๐Ÿ“ Los Angeles Inhibrx Biosciences, Inc ยท Tests: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatiโ€ฆ A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors NCT06031584Phase 1, Phase 21 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1 Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Seoul Yuhan Corporation ยท Tests: YH32364 A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031Phase 22 sites๐Ÿ“ Harbin๐Ÿ“ Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-A1811, SHR-1316, SHR-8068 First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186Phase 110 sites๐Ÿ“ Scottsdale๐Ÿ“ Duarte๐Ÿ“ Orange Plexium, Inc. ยท Tests: PLX-61639 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites๐Ÿ“ Scottsdale๐Ÿ“ Sarasota๐Ÿ“ Chicago Avacta Life Sciences Ltd ยท Tests: AVA6103 A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer NCT06431490Phase 1, Phase 243 sites๐Ÿ“ Fuyang๐Ÿ“ Hefei๐Ÿ“ Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharโ€ฆ ยท Tests: TQB2102 for injection The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites๐Ÿ“ Irvine๐Ÿ“ La Jolla๐Ÿ“ Los Angeles PMV Pharmaceuticals, Inc ยท Tests: rezatapopt, pembrolizumab A Study of YL202 in Patients With Advanced Solid Tumors NCT07202364Phase 21 site๐Ÿ“ Changsha MediLink Therapeutics (Suzhou) Co., Ltd. ยท Tests: YL202 A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors NCT07730021Phase 1, Phase 24 sites๐Ÿ“ Lake Success๐Ÿ“ Fairfax๐Ÿ“ Chuo-ku Astellas Pharma Global Development, Inc. ยท Tests: ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin, 5-fluorouracil Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site๐Ÿ“ Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. ยท Tests: Drug: IBI3028 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors NCT07540572Phase 111 sites๐Ÿ“ Plantation๐Ÿ“ East Brunswick๐Ÿ“ Lake Success IDEAYA Biosciences ยท Tests: IDE574, Fulvestrant injection
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy